Alto Neuroscience completes enrollment in Phase 2 trial for first-of-its-kind schizophrenia cognitive treatment
Alto met its enrollment goal with 83 patients across 13 US clinical sites
Alto met its enrollment goal with 83 patients across 13 US clinical sites
The NIRSE-GAL study, conducted in Galicia, Spain, is the first real-world, population-based investigation of a universal RSV immunization program spanning two consecutive seasons
mNEXSPIKE is the third Moderna vaccine authorized in the European Union, strengthening the Company's respiratory vaccine portfolio in Europe
Dawson joins Roche from the Peter MacCallum Cancer Centre, where he serves as Associate Director of Research
The approval marks a major advance in targeted treatment for this rare, chronic autoimmune disease, offering twice-yearly maintenance dosing after two initial loading doses
Bocunebart works by blocking pituitary adenylate cyclase-activating polypeptide
The company’s consolidated revenues rose 17.5% year-on-year to Rs. 2,265 crore
PBGENE-DMD is designed to permanently correct mutations in the dystrophin gene between exons 45 and 55, the “hot-spot” region affecting roughly 60% of DMD patients
BioAsia 2026 represents a decisive shift toward execution, scale, and global competitiveness, reflecting the rapid evolution of the life sciences ecosystem
Subscribe To Our Newsletter & Stay Updated